PMID- 36555362
OWN - NLM
STAT- MEDLINE
DCOM- 20221226
LR  - 20221226
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 24
DP  - 2022 Dec 11
TI  - Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for 
      the Treatment of Advanced Melanoma.
LID - 10.3390/ijms232415720 [doi]
LID - 15720
AB  - Therapeutic options for treating advanced melanoma have progressed rapidly in 
      recent decades. Until 6 years ago, the regimen for treating advanced melanoma 
      consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. 
      Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as 
      anchor drugs for treating advanced melanoma, with or without additional 
      combination drugs such as ipilimumab, but the efficacies of these immunotherapies 
      are not fully satisfactory. In this review, we describe the development of the 
      currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, 
      focusing on their efficacy and immune-related adverse events (AEs), as well as 
      clinical trials still ongoing for the future treatment of advanced melanoma.
FAU - Fujimura, Taku
AU  - Fujimura T
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
FAU - Muto, Yusuke
AU  - Muto Y
AUID- ORCID: 0000-0002-7180-2786
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
FAU - Asano, Yoshihide
AU  - Asano Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
LA  - eng
GR  - 22ym0126041h0002/Japan Agency for Medical Research and Development/
PT  - Journal Article
PT  - Review
DEP - 20221211
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ipilimumab)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 0 (CTLA-4 Antigen)
SB  - IM
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/therapeutic use
MH  - *Melanoma/drug therapy
MH  - Ipilimumab/therapeutic use
MH  - Immunotherapy
MH  - Dacarbazine/therapeutic use
MH  - CTLA-4 Antigen
PMC - PMC9779655
OTO - NOTNLM
OT  - advanced melanoma
OT  - anti-CTLA4 Abs
OT  - anti-PD1 Abs
OT  - efficacy
OT  - immune checkpoint inhibitors
OT  - irAEs
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/27 06:00
PMCR- 2022/12/11
CRDT- 2022/12/23 01:33
PHST- 2022/11/29 00:00 [received]
PHST- 2022/12/08 00:00 [revised]
PHST- 2022/12/09 00:00 [accepted]
PHST- 2022/12/23 01:33 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/27 06:00 [medline]
PHST- 2022/12/11 00:00 [pmc-release]
AID - ijms232415720 [pii]
AID - ijms-23-15720 [pii]
AID - 10.3390/ijms232415720 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Dec 11;23(24):15720. doi: 10.3390/ijms232415720.